In addition, shRNAs targeting nuclear receptor related 1 (Nurr1) or Src homology region 2 (SH2)-containing protein tyrosine phosphatase 2 (Shp2) were developed as a viable method for treating levodopa-induced dyskinesias (Sellnow et al., 2015). This evidence concerns the gene NR4A2 and Dyskinesia.